Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcitriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GC | P02774 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcitriol SCHEMBL3488822 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2641696 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2733051 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL15169024 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL24066838 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL14027727 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL23386523 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL13989116 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL17973736 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL21055106 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556054-B1 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 | WISCONSIN ALUMNI RES FOUND (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-1831161-B1 | MEDICAL AND COSMETIC USES OF 2-METHYLENE-19-NOR-(20R)-1-ALPHA-HYDROXY-BISHOMOPREGNACALCIFEROL | WISCONSIN ALUMNI RES FOUND (US) | 2017-07-26 | — | — | EP | disclosed |
| US-8604009-B2 | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604008-B2 | 2-methylene-19,21-dinor-1α-hydroxy-bishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8575136-B2 | 2-methylene-1α-hydroxy-18,19,21-trinorvitamin D3 analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-11-05 | — | — | US | disclosed |
| US-8404666-B2 | 2-substituted-1α,25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8222235-B2 | 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2021321-B1 | 2-METHYLENE-1ALPHA,25-DIHYDROXY-18,19,21-TRINORVITAMIN D3 AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-2001841-B1 | 2-METHYLENE-1 ALPHA-HYDROXY-18,19,21-TRINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2001842-B1 | 2-METHYLENE-1ALPHA-HYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RES FOUND (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20060264410-A1 | 19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-11-23 | — | — | US | disclosed |
| US-20060223782-A1 | 2-Methylene-19-nor-(23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-10-05 | — | — | US | disclosed |
| US-20060183721-A1 | 2-Methylene-19-nor-(20S-24epi)-1alpha,25-dihydroxyvitamin D2 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-08-17 | — | — | US | disclosed |
| US-20060183716-A1 | 2-Methylene-19-nor-(20S-24S)-1alpha,25-dihydroxyvitamin D2 | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-08-17 | — | — | US | disclosed |
| US-20060135800-A1 | 2-Methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-06-22 | — | — | US | disclosed |
| US-20060135798-A1 | 2-Methylene-19-nor-(20S)-1alpha-hydroxy-trishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-06-22 | — | — | US | disclosed |
| US-20060135799-A1 | 2-Methylene-19-NOR-(20R)-1alpha-hydroxy-bishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2006-06-22 | — | — | US | disclosed |
| WO-2006057915-A2 | 2-METHYLENE-19,21-DINOR-1ALPHA-HYDROXY-BISHOMOPREGNACALCIFEROL | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20050182033-A1 | Vitamin D receptor antagonists and their use in treating asthma | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-08-18 | — | — | US | disclosed |
| US-20050119242-A1 | Vitamin D analogs for obesity prevention and treatment | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135798-A1 | 2-Methylene-19-nor-(20S)-1alpha-hydroxy-trishomopregnacalciferol | CYP24A1, CYP27B1, CYP46A1 | VDR 34/4885MAPT 4329/4885ADORA3 3913/4885 |
| US-20060264410-A1 | 19,26,27-trinor-1alpha,25-dihydroxyvitamin D3 compounds | CYP24A1, CYP2R1, CYP27B1 | VDR 4/4885MAPT 4331/4885ADORA3 1096/4885 |
| US-20060135799-A1 | 2-Methylene-19-NOR-(20R)-1alpha-hydroxy-bishomopregnacalciferol | CYP2R1, CYP24A1, CYP46A1 | VDR 34/4885MAPT 4456/4885ADORA3 3830/4885 |
| US-20050182033-A1 | Vitamin D receptor antagonists and their use in treating asthma | VDR, CYP2R1, CYP24A1 | VDR 1/4885MAPT 4830/4885ADORA3 163/4885 |
| US-20060183721-A1 | 2-Methylene-19-nor-(20S-24epi)-1alpha,25-dihydroxyvitamin D2 | CYP24A1, CYP27B1, CYP2R1 | VDR 8/4885MAPT 4390/4885ADORA3 2165/4885 |
| US-20050119242-A1 | Vitamin D analogs for obesity prevention and treatment | VDR, CYP24A1, SCD | VDR 1/4885MAPT 4505/4885ADORA3 494/4885 |
| US-20060135800-A1 | 2-Methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol | CYP24A1, CYP27B1, CYP46A1 | VDR 31/4885MAPT 4492/4885ADORA3 3535/4885 |
| US-20060223782-A1 | 2-Methylene-19-nor-(23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone | CYP24A1, CYP2R1, CYP27B1 | VDR 5/4885MAPT 4744/4885ADORA3 1332/4885 |
| US-20060183716-A1 | 2-Methylene-19-nor-(20S-24S)-1alpha,25-dihydroxyvitamin D2 | CYP24A1, CYP27B1, CYP2R1 | VDR 5/4885MAPT 4521/4885ADORA3 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.